Since hematological cases can be treated and prolongation of life is achieved, many different spirituals and psychological concerns must be addressed to maintain smooth functioning and optimize quality of life (QoL). This research study has been designed the first time to place into hematological practice in Armenia.
QoL questionnaire include common and disease related specific problems: over 50 questions about psychological and functional conditions. The questionnaires were first filled out within the 7 days after admittance and after two weeks.
The study of questionnaires revealed that weakness impaired the patients' QoL in 80% (n = 64), the bone pain – in 85% (n= 68), fever- in 75% (n = 60), dyspepsia – in 60% (n = 48), followed by the decreased ability to work – in 60% (n = 48) and lower personal relations – in 62.5% (n = 50) of cases. QoL indicators were dependant on the disease diversity and accompanied risk factors. Patients with high-risk and AML have shown the poorer indicators of QoL then the patients with low-risk and ALL. Acknowledgment and understanding by the patients, that many of side effects and spiritual feelings are impermanent and predictable, may create sense of confidence. Our research data indicates that patients in general trust and are confident in their healthcare practitioners (physicians and nurses). They do also have disclosed the chemotherapy treatment as quite a sensitive financial burden for them. 90% (n= 72) of all patients pointed out their families, friends and fellows as supportive factors. As it's been shown, the side effects of chemotherapy and other cancer-related issues are the most influential factors to decrease the QoL of patients with AL.
The first step towards dealing with the routine chemotherapy treatment is communication. The second step is QoL information: perception that many of depressive feelings are predictable and not fatal, and many of side effects are impermanent, may become meaningful. The modified QoL questionnaire for the patients with AL is one of the well-validated instruments to place into everyday practice to obtain reliable scores and meaningful data on QoL and it should become an integral part in AL treatment decision-making.
Clinical trial identification
All authors have declared no conflicts of interest.